Minghui Pharmaceutical and Qilu Pharmaceutical side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Minghui Pharmaceutical | Qilu Pharmaceutical |
|---|---|---|
| Phase 1 | Minghui Pharmaceutical: 1 of its 11 programs at phase 1
| Qilu Pharmaceutical: 23 of its 71 programs at phase 1
and 18 more — sign in to see them all |
| Phase 2 | Minghui Pharmaceutical: 8 of its 11 programs at phase 2
and 3 more — sign in to see them all | Qilu Pharmaceutical: 14 of its 71 programs at phase 2
and 9 more — sign in to see them all |
| Phase 3 | 18% | Qilu Pharmaceutical: 32 of its 71 programs at phase 3
and 27 more — sign in to see them all |
| Approved, new studies | 00% | Qilu Pharmaceutical: 2 of its 71 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Minghui Pharmaceutical2 readouts · 1 phase 3 | · | Minghui Pharmaceutical, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · | · | Minghui Pharmaceutical, Apr ’27: 1 program whose next study reaches primary completion
| · | · | · | · | · | · |
| Qilu Pharmaceutical36 readouts · 13 phase 3 | Qilu Pharmaceutical, Nov ’26: 2 programs whose next study reaches primary completion
| Qilu Pharmaceutical, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3
and 4 more — sign in to see them all | Qilu Pharmaceutical, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| Qilu Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion
| Qilu Pharmaceutical, Mar ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| Qilu Pharmaceutical, Apr ’27: 5 programs whose next study reaches primary completion, 1 in phase 3
| Qilu Pharmaceutical, May ’27: 4 programs whose next study reaches primary completion, 4 in phase 3
| Qilu Pharmaceutical, Jun ’27: 7 programs whose next study reaches primary completion, 1 in phase 3
and 2 more — sign in to see them all | Qilu Pharmaceutical, Jul ’27: 1 program whose next study reaches primary completion
| Qilu Pharmaceutical, Aug ’27: 1 program whose next study reaches primary completion
| · | Qilu Pharmaceutical, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
|
Changed in the last 90 days
Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Minghui Pharmaceutical
New programs 1
- MHB034C for Injectionphase 2 · first study · Oct 29
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 2
- Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036Cphase 2 · Dec 2025 → Apr 2027 (+16 mo) · moved Oct 16 · NCT06373406
- MHB018Aphase 3 · Jul 2026 → Dec 2026 (+5 mo) · moved Oct 9 · NCT06989918
Qilu Pharmaceutical
New programs 6
- QLS2406-1 injectionphase 1 · first study · Nov 9 · Obesity
- QLS5314phase 1 · first study · Oct 30
- QLS2416phase 1 · first study · Oct 23 · Lupus Erythematosus, Systemic
- QLS2312phase 1 · first study · Sep 30
- QLS2401phase 1 · first study · Sep 30 · Prostatic Neoplasms
- apripitant and palonosetron injectable emulsionphase 1 · first study · Sep 2 · Vomiting
Reached a new phase 2
Study stopped 0
None
Primary completion later 1
- 3-6mg QLM1016phase 3 · Jul 2026 → Oct 2026 (+3 mo) · moved Oct 14 · NCT06799559
Where they overlap
Conditions where at least two of them have programs: 4 in all. A program counts in each condition its studies name most.
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
| Target | Minghui Pharmaceutical | Qilu Pharmaceutical |
|---|---|---|
| CD276 | Anti-B7-H3 Antibody-drug Conjugate MHB088Crule | Anti-B7-H3 Antibody-drug Conjugate MHB088Crule |
| PDCD1 | Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039Arule | Iparomlimab/Tuvonralimabrule |
| TACSTD2 | Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036Crule | Anti-TROP2 Antibody-drug Conjugate ESG401rule |
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.